0001558370-22-006981 10-Q 54 20220331 20220504 20220504 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 10-Q 34 001-39202 22890535 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 10-Q 1 anvs-20220331x10q.htm 10-Q
0.720.4681574456920622815744569206220.720.46NYSENon-accelerated Filer0.0001000081639230001477845--12-312022Q1false8100570P5Y6MP10Y000000001477845us-gaap:CommonStockMember2022-01-012022-03-310001477845us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001477845us-gaap:RetainedEarningsMember2022-03-310001477845us-gaap:AdditionalPaidInCapitalMember2022-03-310001477845us-gaap:RetainedEarningsMember2021-12-310001477845us-gaap:AdditionalPaidInCapitalMember2021-12-310001477845us-gaap:RetainedEarningsMember2021-03-310001477845us-gaap:AdditionalPaidInCapitalMember2021-03-310001477845us-gaap:RetainedEarningsMember2020-12-310001477845us-gaap:AdditionalPaidInCapitalMember2020-12-310001477845us-gaap:CommonStockMember2022-03-310001477845us-gaap:CommonStockMember2021-12-310001477845us-gaap:CommonStockMember2021-03-310001477845us-gaap:CommonStockMember2020-12-310001477845us-gaap:CommonStockMemberanvs:SecondaryPublicOfferingMember2021-05-260001477845anvs:PreviousPlansMember2022-03-310001477845anvs:EquityIncentivePlan2019Member2022-03-310001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845anvs:EquityIncentivePlan2019Member2021-05-310001477845us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001477845us-gaap:CommonStockMemberanvs:SecondaryPublicOfferingMember2021-05-262021-05-260001477845us-gaap:RetainedEarningsMember2022-01-012022-03-310001477845us-gaap:RetainedEarningsMember2021-01-012021-03-310001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2022-03-310001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2021-12-310001477845anvs:UnderwritersWarrantsMember2022-03-310001477845anvs:UnderwritersWarrantsMember2021-12-3100014778452021-03-3100014778452020-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001477845us-gaap:WarrantMember2022-01-012022-03-310001477845us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001477845us-gaap:WarrantMember2021-01-012021-03-310001477845us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001477845us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100014778452022-05-0200014778452021-01-012021-12-310001477845us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001477845us-gaap:CommonStockMember2021-01-012021-03-310001477845anvs:UnderwritersWarrantsMember2020-01-310001477845srt:ExecutiveOfficerMember2022-03-310001477845us-gaap:LicenseAgreementTermsMember2021-07-012021-07-310001477845us-gaap:LicenseAgreementTermsMember2020-01-012020-11-300001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2022-01-012022-03-310001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2021-01-012021-03-3100014778452021-01-012021-03-310001477845anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember2019-09-3000014778452022-01-012022-03-310001477845us-gaap:LicenseAgreementTermsMember2021-07-310001477845anvs:UnderwritersWarrantsMember2021-01-012021-12-3100014778452020-01-3100014778452022-03-3100014778452021-12-31iso4217:USDxbrli:sharesanvs:itemanvs:Votexbrli:pureiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 001-39202

Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

26-2540421

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of registrant’s principal executive offices)

(610727-3913

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

    

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

ANVS

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No.

The number of outstanding shares of the registrant’s common stock as of May 2, 2022 was: 8,163,923.

ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2022

PART I – FINANCIAL INFORMATION

   

Page

Item 1.

Financial Statements

3

Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021

3

Statements of Operations for the Three Months Ended March 31, 2022 and 2021 (Unaudited)

4

Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2022 and 2021 (Unaudited)

5

Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 (Unaudited)

6

Notes to Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 3.

Quantitative and Qualitative Disclosure About Market Risk

19

Item 4.

Controls and Procedures

19

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

20

Item 1A.

Risk Factors

20

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

20

Item 3.

Defaults Upon Senior Securities

20

Item 4.

Mine Safety Disclosures

20

Item 5.

Other Information

20

Item 6.

Exhibits

21

Signatures

22

2

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets

    

March 31, 

December 31, 

    

2022

    

2021

(unaudited)

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

42,668,838

$

45,686,014

Prepaid expenses and other current assets

 

627,902

 

315,464

Total current assets

 

43,296,740

 

46,001,478

Total assets

$

43,296,740

$

46,001,478

Liabilities and Stockholders’ Equity

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

928,997

$

688,074

Accrued expenses

 

327,435

 

818,440

Total current liabilities

 

1,256,432

 

1,506,514

Total liabilities

 

1,256,432

 

1,506,514

Commitments and contingencies (Note 7)

 

  

 

  

Stockholders’ equity:

 

  

 

  

Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding

Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

 

816

 

810

Additional paid-in capital

 

76,659,912

 

73,220,361

Accumulated deficit

 

(34,620,420)

 

(28,726,207)

Total stockholders’ equity

 

42,040,308

 

44,494,964

Total liabilities and stockholders’ equity

$

43,296,740

$

46,001,478

See accompanying notes to financial statements.

3

Annovis Bio, Inc.

Statements of Operations

(unaudited)

Three Months Ended

March 31, 

2022

    

2021

    

Operating expenses:

  

 

  

Research and development

$

2,809,791

$

2,389,583

General and administrative

 

3,104,071

 

839,627

Total operating expenses

 

5,913,862

 

3,229,210

Operating loss

 

(5,913,862)

 

(3,229,210)

Other income:

 

  

 

  

Interest income

 

19,649

 

197

Grant income

 

 

29,340

Total other income

 

19,649

 

29,537

Loss before income taxes

 

(5,894,213)

 

(3,199,673)

Income tax expense (benefit)

 

 

Net loss

$

(5,894,213)

$

(3,199,673)

Basic and diluted loss per common share

$

(0.72)

$

(0.46)

Weighted average number of common shares outstanding, basic and diluted

 

8,157,445

 

6,920,622

See accompanying notes to financial statements.

4

Annovis Bio, Inc.

Statements of Changes in Stockholders’ Equity

(unaudited)

Additional

Total

Common Stock

Paid-In

Accumulated

Stockholders'

    

Shares

    

Amount

    

Capital

    

Deficit

    

Equity

Three Months Ended March 31, 2022

Balance, December 31, 2021

 

8,100,570

$

810

$

73,220,361

$

(28,726,207)

$

44,494,964

Exercise of stock options

 

63,353

6

4,607

 

 

4,613

Stock-based compensation expense

3,434,944

3,434,944

Net loss

 

 

 

(5,894,213)

 

(5,894,213)

Balance, March 31, 2022

8,163,923

$

816

$

76,659,912

$

(34,620,420)

$

42,040,308

Three Months Ended March 31, 2021

Balance, December 31, 2020

 

6,891,608

$

689

$

21,779,340

$

(14,239,075)

$

7,540,954

Exercise of stock options

 

3,868

 

1

 

3,016

 

 

3,017

Cashless exercise of warrants

 

51,644

 

5

 

(5)

 

 

Stock-based compensation expense

 

23,977

23,977

Net loss

 

 

 

 

(3,199,673)

 

(3,199,673)

Balance, March 31, 2021

 

6,947,120

$

695

$

21,806,328

$

(17,438,748)

$

4,368,275

See accompanying notes to financial statements.

5

Annovis Bio, Inc.

Statements of Cash Flows

(unaudited)

Three Months Ended March 31, 

2022

2021

Cash flows from operating activities:

  

 

  

Net loss

$

(5,894,213)

$

(3,199,673)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Stock-based compensation expense

 

3,434,944

 

23,977

Changes in operating assets and liabilities:

 

 

Prepaid expenses and other current assets

 

(312,438)

 

(317,473)

Accounts payable

 

240,923

 

482,709

Accrued expenses

 

(491,005)

 

535,592

Net cash used in operating activities

 

(3,021,789)

 

(2,474,868)

Cash flows from financing activities:

 

  

 

  

Proceeds from exercise of stock options

 

4,613

 

3,017

Net cash provided by financing activities

 

4,613

 

3,017

Net decrease in cash and cash equivalents

 

(3,017,176)

 

(2,471,851)

Cash and cash equivalents, beginning of period

 

45,686,014

 

8,074,658

Cash and cash equivalents, end of period

$

42,668,838

$

5,602,807

See accompanying notes to financial statements.

6

Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) is a clinical-stage drug platform company addressing Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and other chronic neurodegenerative diseases, including AD in Down syndrome (“AD-DS”). The Company’s lead compound, buntanetap, is a small, once a day, orally administered, brain penetrant compound. In several clinical and pre-clinical studies, buntanetap inhibited the synthesis of neurotoxic proteins—APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities. On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.6 million, after deducting underwriting discounts and issuance costs. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months including one planned six-month clinical trial in early PD patients and one potential short-term trial in early AD patients. To fund additional expected Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2022, and its results of operations and its cash flows for the three months ended March 31, 2022 and 2021. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to

7

U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include stock-based compensation expense, progress toward completion of research and development projects, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional

8

information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2022 or December 31, 2021.

(k) Recent Accounting Pronouncements

In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. The adoption of this standard did not have a significant impact on the Company’s financial statements.

9

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:

    

    

Fair Value Measurement at

March 31, 2022

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

42,668,838

$

42,668,838

$

$

    

    

Fair Value Measurement at

December 31, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

45,686,014

$

45,686,014

$

$

(4) Grant Income

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $29,340 for the three months ended March 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $0 and $29,340 during the three months ended March 31, 2022 and 2021, respectively. The Company recorded a grant receivable of $0 as of March 31, 2022 and December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of March 31, 2022, there were no remaining funds available under the grant.

10

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

    

March 31, 

December 31, 

2022

2021

Prepaid clinical trial expenses

$

258,361

$

232,752

Prepaid insurance

313,119

29,111

Prepaid expenses

 

46,557

 

43,736

Security deposits

 

9,865

 

9,865

$

627,902

$

315,464

(6) Accrued Expenses

Accrued expenses consisted of the following:

    

March 31, 

December 31, 

2022

2021

Payroll and related benefits

$

168,515

$

712,768

Accrued professional and clinical fees

 

158,920

 

105,672

$

327,435

$

818,440

(7) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $17,276 and $10,615 for the three months ended March 31, 2022 and 2021, respectively.

(b) License Agreement

The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date. No milestones had been achieved as of the termination date.

(c) Employment Agreements

The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately $986,000 at March 31, 2022.

11

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

At March 31, 2022, the Company did not have any pending legal actions.

(e) Risks and Uncertainties

The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

(8) Stockholders’ Equity

(a) Overview

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”), to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of March 31, 2022 or December 31, 2021.

(d) Warrants

In conjunction with the closing of the Company’s IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial

12

public offering price. The warrants have a five-year term and were exercisable as of January 29, 2021. During the year ended December 31, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of March 31, 2022 and December 31, 2021, 2,400 of the warrants were outstanding. The Company accounts for the warrants as a component of stockholders’ equity.

(9) Stock-Based Compensation

The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective on January 31, 2020, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of March 31, 2022, 442,275 shares were available for future grants.

Stock-based compensation expense was as follows:

Three Months Ended

March 31, 

    

2022

    

2021

General and administrative

$

2,245,043

$

23,977

Research and development

 

1,189,901

 

$

3,434,944

$

23,977

During the three months ended March 31, 2022, the Company granted options to purchase 188,294 shares of common stock at an exercise price of $19.78 per share to employees, members of its board of directors and consultants. Under the grant agreements, the options generally vest in substantially equal quarterly installments over two years and have a 10-year term. The options granted during the three months ended March 31, 2022 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.5 years; (ii) risk free interest rate of 1.42%; (iii) expected volatility of 114.0%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the three months ended March 31, 2022 was $16.36 per share.

Stock options exercised during the three months ended March 31, 2022 and 2021, were 70,101 and 3,868, respectively. As of March 31, 2022, there were 1,607,941 options outstanding, of which 1,211,193 were vested and exercisable. As of December 31, 2021, there were 1,489,748 options outstanding, of which 1,105,568 were vested and exercisable.

(10) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended

March 31, 

    

2022

    

2021

    

Numerator

 

  

 

  

Net loss

$

(5,894,213)

$

(3,199,673)

Denominator

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,157,445

 

6,920,622

Net loss per share, basic and diluted

$

(0.72)

$

(0.46)

The Company reported a net loss for the three months ended March 31, 2022 and 2021, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would

13

have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

March 31, 

    

2022

    

2021

Stock options

1,607,941

1,107,598

Warrants

 

2,400

 

5,000

(11) Income Taxes

The Company’s income tax benefit (expense) was $0 for the three months ended March 31, 2022 and 2021. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three months ended March 31, 2022 and 2021 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of March 31, 2022, and December 31, 2021, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our business strategies;
the timing of regulatory submissions;
our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;
risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;
risks related to market acceptance of products;
risks associated with our reliance on third-party organizations;
our competitive position;
assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;
our intellectual property position and our ability to maintain and protect our intellectual property rights;
our results of operations, financial condition, liquidity, prospects, and growth strategies;
our cash needs and financing plans;
the industry in which we operate; and
the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in “Factors that May Affect Future Results” below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

15

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2021 which are included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Company Overview

We are a clinical stage, drug platform company addressing Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and other chronic neurodegenerative diseases, including AD in Down Syndrome (“AD-DS”). Our lead compound, buntanetap is a small, once a day, orally administered, brain penetrant compound. In several clinical and pre-clinical studies, buntanetap inhibited the synthesis of neurotoxic proteins—amyloid precursor protein APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)— that are the main causes of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have shown in our clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

We recently completed two Phase 2a clinical trials. In 2021 we completed a Phase 2a clinical trial in 14 AD and 54 PD patients (the “AD/PD Trial”) which began treating patients in August 2020. In collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”) we conducted a trial in 16 early AD patients (the “ADCS Trial”). Both clinical trials were double-blind, placebo-controlled studies. We designed the two Phase 2a studies by applying our understanding of the underlying disease states in neurodegeneration and measured not just target, but also pathway validation in the spinal fluid of these patients. We measured as many factors as possible associated with the toxic cascade which begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, the death of nerve cells and loss of cognition and motor function. By showing both target and pathway validation in two patient populations, we believe that our opportunity for successful Phase 3 studies is better than if we merely demonstrated target validation in one patient population.

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at March 31, 2022 was $34,620.4 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

16

Results of Operations

Operating expenses and other income were comprised of the following:

Three Months Ended

March 31, 

    

2022

    

2021

(in thousands)

Operating expenses:

Research and development

$

2,809.8

    

$

2,389.6

General and administrative

$

3,104.1

$

839.6

Other income:

Interest income

$

19.6

$

0.2

Grant income

$

$

29.3

Three Months Ended March 31, 2022 and 2021

Research and Development Expenses

Research and development expenses increased by $420.2 thousand for the three months ended March 31, 2022 compared to the prior year period. The increase was primarily the result of an increase of $1,189.9 thousand in stock-based compensation expense, partially offset by a decrease of $740.8 thousand in expenses related to our clinical trials as we completed the AD/PD Trial in 2021. We expect research and development expenses in 2022 will be higher than the prior year as we begin a Phase 3 study in early PD patients.

General and Administrative Expenses

General and administrative expenses increased by $2,264.5 thousand for the three months ended March 31, 2022 compared to the prior year period. The increase was primarily the result of increases of $2,221.1 thousand in stock-based compensation expense and $105.4 thousand in professional fees. We expect general and administrative expenses in 2022 will be higher as compared to 2021 due to increased personnel expenses.

Interest Income

Interest income increased $19.4 thousand for the three months ended March 31, 2022 compared to the prior year period. The increase was primarily the result of higher average cash and cash equivalents balances and higher interest rates compared to the prior year period.

Grant Income

Grant income decreased $29.3 thousand for the three months ended March 31, 2022 compared to the prior year period. The income relates to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which was completed in 2021.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock, and convertible promissory notes and funding from research grants. To date, we have not generated any revenue from the sale of products, and we do not anticipate generating any revenue from the sale of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of March 31, 2022, our principal source of liquidity was our cash, which totaled $42,668.8 thousand.

17

Equity Financings

We closed an equity offering on May 26, 2021, raising gross proceeds of $50,000.0 thousand and net proceeds of $46,648.4 thousand, after deducting underwriting discounts and issuance costs.

Cash Flows

The following table summarizes our cash flows for the respective period:

Three Months Ended

March 31, 

    

2022

    

2021

(in thousands)

Statement of Cash Flows Data:

 

  

    

  

Total net cash provided by (used in):

 

  

 

  

Operating activities

$

(3,021.8)

$

(2,474.9)

Financing activities

 

4.6

 

3.0

Net decrease in cash and cash equivalents

$

(3,017.2)

$

(2,471.9)

Operating Activities

For the three months ended March 31, 2022, cash used in operations increased $546.9 thousand compared to the same period in the prior year. The increase in cash used in operations was primarily the result of an increase in cash payments to satisfy accrued expenses.

We expect cash used in operating activities to increase in 2022 as compared to 2021 due to an expected increase in our operating losses associated with ongoing development of our product candidates, including clinical trial expenses for our planned Phase 3 trial in early PD patients and a second clinical trial in early AD patients.

Financing Activities

Cash provided by financing activities was $4.6 thousand during the three months ended March 31, 2022, attributable to proceeds from the exercise of stock options.

Cash provided by financing activities was $3.0 thousand during the three months ended March 31, 2021, attributable to proceeds from the exercise of stock options.

Funding Requirements

We expect that current cash and cash equivalents will be sufficient to fund our operations and capital requirements for at least the next 12 months. We believe that these available funds will be sufficient to complete a six-month Phase 3 clinical trial for buntanetap in early PD patients and conduct a second study in early AD patients for this product candidate. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

18

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 for a discussion of important factors that may affect our future results.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the three months ended March 31, 2022, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2021, which we included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

19

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

This item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

20

Item 6. Exhibits

Exhibit
Number

    

Description of Exhibit

 

3.1

Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.)

 

3.2

Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.)

31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature

    

Title

    

Date

 

 

 

/s/ MARIA MACCECCHINI

President and Chief Executive Officer (principal

May 4, 2022

Maria Maccecchini

executive officer)

 

 

 

/s/ JEFFREY MCGROARTY

Chief Financial Officer (principal financial and

May 4, 2022

Jeffrey McGroarty

accounting officer)

22

EX-31.1 2 anvs-20220331xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2022

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-31.2 3 anvs-20220331xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey McGroarty, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2022

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-32.1 4 anvs-20220331xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2022

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-32.2 5 anvs-20220331xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey McGroarty, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2022

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-101.SCH 6 anvs-20220331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Grant Income (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Commitments and Contingencies - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stockholders' Equity - Overview (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Grant Income link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 anvs-20220331_cal.xml EX-101.CAL EX-101.DEF 8 anvs-20220331_def.xml EX-101.DEF EX-101.LAB 9 anvs-20220331_lab.xml EX-101.LAB EX-101.PRE 10 anvs-20220331_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 02, 2022
Document and Entity Information    
Entity Registrant Name Annovis Bio, Inc.  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-39202  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-2540421  
Entity Address, Address Line One 1055 Westlakes Drive, Suite 300  
Entity Address, City or Town Berwyn  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19312  
City Area Code 610  
Local Phone Number 727-3913  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol ANVS  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   8,163,923
Entity Central Index Key 0001477845  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 42,668,838 $ 45,686,014
Prepaid expenses and other current assets 627,902 315,464
Total current assets 43,296,740 46,001,478
Total assets 43,296,740 46,001,478
Current liabilities:    
Accounts payable 928,997 688,074
Accrued expenses 327,435 818,440
Total current liabilities 1,256,432 1,506,514
Total liabilities 1,256,432 1,506,514
Commitments and contingencies (Note 7)
Stockholders' equity    
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 816 810
Additional paid-in capital 76,659,912 73,220,361
Accumulated deficit (34,620,420) (28,726,207)
Total stockholders' equity 42,040,308 44,494,964
Total liabilities and stockholders' equity $ 43,296,740 $ 46,001,478
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Balance Sheets    
Preferred stock, par value (dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 8,163,923 8,100,570
Common stock, shares outstanding 8,163,923 8,100,570
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 2,809,791 $ 2,389,583
General and administrative 3,104,071 839,627
Total operating expenses 5,913,862 3,229,210
Operating loss (5,913,862) (3,229,210)
Other income:    
Interest income 19,649 197
Grant income   29,340
Total other income 19,649 29,537
Loss before income taxes (5,894,213) (3,199,673)
Income tax expense (benefit) 0 0
Net loss $ (5,894,213) $ (3,199,673)
Basic loss per common share $ (0.72) $ (0.46)
Diluted loss per common share $ (0.72) $ (0.46)
Weighted average number of common shares outstanding, basic 8,157,445 6,920,622
Weighted average number of common shares outstanding, diluted 8,157,445 6,920,622
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Changes in Stockholders' Equity - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2020 $ 689 $ 21,779,340 $ (14,239,075) $ 7,540,954
Balance, shares at Dec. 31, 2020 6,891,608      
Changes in Stockholders' Equity        
Exercise of stock options $ 1 3,016   3,017
Exercise of stock options, shares 3,868      
Cashless exercise of warrants $ 5 (5)    
Cashless exercise of warrants, shares 51,644      
Stock based compensation expense   23,977   23,977
Net loss     (3,199,673) (3,199,673)
Balance at Mar. 31, 2021 $ 695 21,806,328 (17,438,748) 4,368,275
Balance, shares at Mar. 31, 2021 6,947,120      
Balance at Dec. 31, 2021 $ 810 73,220,361 (28,726,207) 44,494,964
Balance, shares at Dec. 31, 2021 8,100,570      
Changes in Stockholders' Equity        
Exercise of stock options $ 6 4,607   4,613
Exercise of stock options, shares 63,353      
Stock based compensation expense   3,434,944   3,434,944
Net loss     (5,894,213) (5,894,213)
Balance at Mar. 31, 2022 $ 816 $ 76,659,912 $ (34,620,420) $ 42,040,308
Balance, shares at Mar. 31, 2022 8,163,923      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (5,894,213) $ (3,199,673)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 3,434,944 23,977
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (312,438) (317,473)
Accounts payable 240,923 482,709
Accrued expenses (491,005) 535,592
Net cash used in operating activities (3,021,789) (2,474,868)
Cash flows from financing activities:    
Proceeds from exercise of stock options 4,613 3,017
Net cash provided by financing activities 4,613 3,017
Net decrease in cash and cash equivalents (3,017,176) (2,471,851)
Cash and cash equivalents, beginning of period 45,686,014 8,074,658
Cash and cash equivalents, end of period $ 42,668,838 $ 5,602,807
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Liquidity
3 Months Ended
Mar. 31, 2022
Nature of Business and Liquidity  
Nature of Business and Liquidity

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) is a clinical-stage drug platform company addressing Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and other chronic neurodegenerative diseases, including AD in Down syndrome (“AD-DS”). The Company’s lead compound, buntanetap, is a small, once a day, orally administered, brain penetrant compound. In several clinical and pre-clinical studies, buntanetap inhibited the synthesis of neurotoxic proteins—APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities. On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0 million. The net proceeds of the offering were approximately $46.6 million, after deducting underwriting discounts and issuance costs. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months including one planned six-month clinical trial in early PD patients and one potential short-term trial in early AD patients. To fund additional expected Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2022, and its results of operations and its cash flows for the three months ended March 31, 2022 and 2021. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to

U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include stock-based compensation expense, progress toward completion of research and development projects, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional

information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2022 or December 31, 2021.

(k) Recent Accounting Pronouncements

In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. The adoption of this standard did not have a significant impact on the Company’s financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2022
Fair Value Measurements  
Fair Value Measurements

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:

    

    

Fair Value Measurement at

March 31, 2022

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

42,668,838

$

42,668,838

$

$

    

    

Fair Value Measurement at

December 31, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

45,686,014

$

45,686,014

$

$

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Grant Income
3 Months Ended
Mar. 31, 2022
Grant Income  
Grant Income

(4) Grant Income

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $29,340 for the three months ended March 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $0 and $29,340 during the three months ended March 31, 2022 and 2021, respectively. The Company recorded a grant receivable of $0 as of March 31, 2022 and December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of March 31, 2022, there were no remaining funds available under the grant.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets
3 Months Ended
Mar. 31, 2022
Prepaid Expenses and Other Current Assets  
Prepaid Expenses and Other Current Assets

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

    

March 31, 

December 31, 

2022

2021

Prepaid clinical trial expenses

$

258,361

$

232,752

Prepaid insurance

313,119

29,111

Prepaid expenses

 

46,557

 

43,736

Security deposits

 

9,865

 

9,865

$

627,902

$

315,464

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses
3 Months Ended
Mar. 31, 2022
Accrued Expenses  
Accrued Expenses

(6) Accrued Expenses

Accrued expenses consisted of the following:

    

March 31, 

December 31, 

2022

2021

Payroll and related benefits

$

168,515

$

712,768

Accrued professional and clinical fees

 

158,920

 

105,672

$

327,435

$

818,440

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies  
Commitments and Contingencies

(7) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $17,276 and $10,615 for the three months ended March 31, 2022 and 2021, respectively.

(b) License Agreement

The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.

In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date. No milestones had been achieved as of the termination date.

(c) Employment Agreements

The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately $986,000 at March 31, 2022.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

At March 31, 2022, the Company did not have any pending legal actions.

(e) Risks and Uncertainties

The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2022
Stockholders' Equity  
Stockholders' Equity

(8) Stockholders’ Equity

(a) Overview

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”), to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of March 31, 2022 or December 31, 2021.

(d) Warrants

In conjunction with the closing of the Company’s IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial

public offering price. The warrants have a five-year term and were exercisable as of January 29, 2021. During the year ended December 31, 2021, 97,600 of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of March 31, 2022 and December 31, 2021, 2,400 of the warrants were outstanding. The Company accounts for the warrants as a component of stockholders’ equity.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2022
Stock-Based Compensation  
Stock-Based Compensation

(9) Stock-Based Compensation

The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective on January 31, 2020, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of March 31, 2022, 442,275 shares were available for future grants.

Stock-based compensation expense was as follows:

Three Months Ended

March 31, 

    

2022

    

2021

General and administrative

$

2,245,043

$

23,977

Research and development

 

1,189,901

 

$

3,434,944

$

23,977

During the three months ended March 31, 2022, the Company granted options to purchase 188,294 shares of common stock at an exercise price of $19.78 per share to employees, members of its board of directors and consultants. Under the grant agreements, the options generally vest in substantially equal quarterly installments over two years and have a 10-year term. The options granted during the three months ended March 31, 2022 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of 5.5 years; (ii) risk free interest rate of 1.42%; (iii) expected volatility of 114.0%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the three months ended March 31, 2022 was $16.36 per share.

Stock options exercised during the three months ended March 31, 2022 and 2021, were 70,101 and 3,868, respectively. As of March 31, 2022, there were 1,607,941 options outstanding, of which 1,211,193 were vested and exercisable. As of December 31, 2021, there were 1,489,748 options outstanding, of which 1,105,568 were vested and exercisable.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2022
Net Loss Per Share  
Net Loss Per Share

(10) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended

March 31, 

    

2022

    

2021

    

Numerator

 

  

 

  

Net loss

$

(5,894,213)

$

(3,199,673)

Denominator

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,157,445

 

6,920,622

Net loss per share, basic and diluted

$

(0.72)

$

(0.46)

The Company reported a net loss for the three months ended March 31, 2022 and 2021, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would

have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

March 31, 

    

2022

    

2021

Stock options

1,607,941

1,107,598

Warrants

 

2,400

 

5,000

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Taxes  
Income Taxes

(11) Income Taxes

The Company’s income tax benefit (expense) was $0 for the three months ended March 31, 2022 and 2021. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three months ended March 31, 2022 and 2021 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of March 31, 2022, and December 31, 2021, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Summary of Significant Accounting Policies  
Basis of Presentation of Interim Unaudited Financial Statements

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2022, and its results of operations and its cash flows for the three months ended March 31, 2022 and 2021. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to

U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

Use of Estimates

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include stock-based compensation expense, progress toward completion of research and development projects, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

Basic and Diluted Net Income (Loss) per Share

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

Cash and Cash Equivalents

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.

Issuance Costs Associated with Equity Issuances

(e)  Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

Fair Value of Financial Instruments

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

Research and Development

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional

information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

Grant Income

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

Stock-Based Compensation

(i) Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

Income Taxes

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2022 or December 31, 2021.

Recent Accounting Pronouncements

(k) Recent Accounting Pronouncements

In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. The adoption of this standard did not have a significant impact on the Company’s financial statements.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2022
Fair Value Measurements  
Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:

    

    

Fair Value Measurement at

March 31, 2022

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

42,668,838

$

42,668,838

$

$

    

    

Fair Value Measurement at

December 31, 2021

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

45,686,014

$

45,686,014

$

$

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets (Tables)
3 Months Ended
Mar. 31, 2022
Prepaid Expenses and Other Current Assets  
Schedule of prepaid expenses and other current assets

    

March 31, 

December 31, 

2022

2021

Prepaid clinical trial expenses

$

258,361

$

232,752

Prepaid insurance

313,119

29,111

Prepaid expenses

 

46,557

 

43,736

Security deposits

 

9,865

 

9,865

$

627,902

$

315,464

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2022
Accrued Expenses  
Schedule of accrued expenses

    

March 31, 

December 31, 

2022

2021

Payroll and related benefits

$

168,515

$

712,768

Accrued professional and clinical fees

 

158,920

 

105,672

$

327,435

$

818,440

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2022
Stock-Based Compensation  
Schedule of stock-based compensation expense

Three Months Ended

March 31, 

    

2022

    

2021

General and administrative

$

2,245,043

$

23,977

Research and development

 

1,189,901

 

$

3,434,944

$

23,977

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2022
Net Loss Per Share  
Schedule of basic and diluted net loss per share

Three Months Ended

March 31, 

    

2022

    

2021

    

Numerator

 

  

 

  

Net loss

$

(5,894,213)

$

(3,199,673)

Denominator

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

8,157,445

 

6,920,622

Net loss per share, basic and diluted

$

(0.72)

$

(0.46)

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding

March 31, 

    

2022

    

2021

Stock options

1,607,941

1,107,598

Warrants

 

2,400

 

5,000

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business and Liquidity (Details) - USD ($)
3 Months Ended
May 26, 2021
Mar. 31, 2022
Nature of Business and Liquidity    
Revenue   $ 0
Common Stock | Secondary Public Offering    
Nature of Business and Liquidity    
Issuance of common stock 1,000,000  
Share price $ 50.00  
Gross proceeds from issuance of common shares $ 50,000,000.0  
Net proceeds from issuance of common shares $ 46,600,000  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Fair Value Measurements    
Cash and cash equivalents, Carrying Value $ 42,668,838 $ 45,686,014
Recurring | Level 1    
Fair Value Measurements    
Cash and cash equivalents, Fair Value $ 42,668,838 $ 45,686,014
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Grant Income (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Sep. 30, 2019
Grant Income        
Grant income   $ 29,340    
Unreimbursed, eligible costs incurred under the grant $ 0   $ 0  
Remining funds available 0      
NIH        
Grant Income        
Notice of Award, grant amount       $ 1,900,000
Grant income 0 29,340    
Proceeds from Grants 0 $ 29,340    
Grant receivable $ 0   $ 0  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Prepaid Expenses and Other Current Assets    
Prepaid clinical trial expenses $ 258,361 $ 232,752
Prepaid insurance 313,119 29,111
Prepaid expenses 46,557 43,736
Security deposit 9,865 9,865
Total prepaid expenses and other current assets $ 627,902 $ 315,464
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Accrued Expenses    
Payroll and related benefits $ 168,515 $ 712,768
Accrued professional and clinical fees 158,920 105,672
Total accrued expenses $ 327,435 $ 818,440
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Leases (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Leases    
Rental expense $ 17,276 $ 10,615
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - License Agreement (Details) - License Agreement
1 Months Ended 11 Months Ended
Jul. 31, 2021
USD ($)
Nov. 30, 2020
USD ($)
Commitments and Contingencies    
Minimum annual fee   $ 46,000
Period for advance notice of termination 90 days  
Number of milestones achieved 0  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Employment Agreements (Details)
Mar. 31, 2022
USD ($)
Executive Officers  
Employment Agreements  
Maximum aggregate severance payments $ 986,000
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Overview (Details)
Mar. 31, 2022
Vote
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Jan. 31, 2020
item
$ / shares
shares
Stockholders' Equity      
Number of classes of stock designated | item     2
Number of common and preferred shares authorized     37,000,000
Common stock, par value (dollars per share) | $ / shares $ 0.0001 $ 0.0001 $ 0.0001
Preferred stock, par value (dollars per share) | $ / shares $ 0.0001 $ 0.0001 $ 0.0001
Number of common shares authorized 35,000,000 35,000,000 35,000,000
Number of preferred shares authorized 2,000,000 2,000,000 2,000,000
Number of vote for each share of common stock | Vote 1    
Preferred stock, shares issued 0 0  
Preferred stock, shares outstanding 0 0  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Warrants (Details) - Underwriters warrants - $ / shares
12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Jan. 31, 2020
Warrants      
Number of warrants issued     100,000
Exercise price     $ 7.50
Percentage of exercise price to the share offering price     125.00%
Warrant term     5 years
Number of warrants converted in a non-cash transaction 97,600    
Warrants outstanding 2,400 2,400  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 01, 2021
May 31, 2021
Stock-Based Compensation          
Options outstanding 1,607,941   1,489,748    
Options granted 188,294        
Exercise price $ 19.78        
Stock-based compensation expense $ 3,434,944 $ 23,977      
Options, vested and exercisable 1,211,193   1,105,568    
General and administrative          
Stock-Based Compensation          
Stock-based compensation expense $ 2,245,043 $ 23,977      
Research and development          
Stock-Based Compensation          
Stock-based compensation expense $ 1,189,901        
Stock Options          
Stock-Based Compensation          
Vesting period 2 years        
Term of award (in years) 10 years        
Expected term (in years) 5 years 6 months        
Risk-free interest rate 1.42%        
Expected volatility 114.00%        
Dividend yield (as a percent) 0.00%        
Weighted average grant date fair value $ 16.36        
Exercise of stock options, shares 70,101 3,868      
Previous Plans          
Stock-Based Compensation          
Shares available for future grants 0        
2019 Plan          
Stock-Based Compensation          
Shares authorized       2,000,000 1,000,000
Shares available for future grants 442,275        
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator    
Net loss $ (5,894,213) $ (3,199,673)
Denominator    
Weighted-average common shares outstanding, basic 8,157,445 6,920,622
Weighted-average common shares outstanding, diluted 8,157,445 6,920,622
Net loss per share, basic $ (0.72) $ (0.46)
Net loss per share, diluted $ (0.72) $ (0.46)
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share - Potential shares excluded from calculation (Details) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Stock Options    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 1,607,941 1,107,598
Warrants    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 2,400 5,000
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Income Taxes      
Income tax expense (benefit) $ 0 $ 0  
Liability for uncertain tax positions 0   $ 0
Accrued interest or penalties $ 0   $ 0
XML 48 anvs-20220331x10q_htm.xml IDEA: XBRL DOCUMENT 0001477845 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2022-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001477845 us-gaap:RetainedEarningsMember 2021-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001477845 us-gaap:RetainedEarningsMember 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001477845 us-gaap:RetainedEarningsMember 2020-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001477845 us-gaap:CommonStockMember 2022-03-31 0001477845 us-gaap:CommonStockMember 2021-12-31 0001477845 us-gaap:CommonStockMember 2021-03-31 0001477845 us-gaap:CommonStockMember 2020-12-31 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 0001477845 anvs:PreviousPlansMember 2022-03-31 0001477845 anvs:EquityIncentivePlan2019Member 2022-03-31 0001477845 anvs:EquityIncentivePlan2019Member 2021-06-01 0001477845 anvs:EquityIncentivePlan2019Member 2021-05-31 0001477845 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001477845 us-gaap:CommonStockMember anvs:SecondaryPublicOfferingMember 2021-05-26 2021-05-26 0001477845 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001477845 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2022-03-31 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-12-31 0001477845 anvs:UnderwritersWarrantsMember 2022-03-31 0001477845 anvs:UnderwritersWarrantsMember 2021-12-31 0001477845 2021-03-31 0001477845 2020-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001477845 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001477845 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001477845 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001477845 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001477845 2022-05-02 0001477845 2021-01-01 2021-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001477845 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001477845 anvs:UnderwritersWarrantsMember 2020-01-31 0001477845 srt:ExecutiveOfficerMember 2022-03-31 0001477845 us-gaap:LicenseAgreementTermsMember 2021-07-01 2021-07-31 0001477845 us-gaap:LicenseAgreementTermsMember 2020-01-01 2020-11-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2022-01-01 2022-03-31 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2021-01-01 2021-03-31 0001477845 2021-01-01 2021-03-31 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2019-09-30 0001477845 2022-01-01 2022-03-31 0001477845 us-gaap:LicenseAgreementTermsMember 2021-07-31 0001477845 anvs:UnderwritersWarrantsMember 2021-01-01 2021-12-31 0001477845 2020-01-31 0001477845 2022-03-31 0001477845 2021-12-31 iso4217:USD shares anvs:item anvs:Vote pure iso4217:USD shares -0.72 -0.46 8157445 6920622 8157445 6920622 -0.72 -0.46 NYSE Non-accelerated Filer 0.0001 0 0 0 0 8163923 0001477845 --12-31 2022 Q1 false 8100570 P5Y6M P10Y 0 0 0 0 0 10-Q true 2022-03-31 false 001-39202 Annovis Bio, Inc. DE 26-2540421 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS Yes Yes true true true false 8163923 42668838 45686014 627902 315464 43296740 46001478 43296740 46001478 928997 688074 327435 818440 1256432 1506514 1256432 1506514 0.0001 0.0001 2000000 2000000 0 0 0.0001 0.0001 35000000 35000000 8163923 8100570 816 810 76659912 73220361 -34620420 -28726207 42040308 44494964 43296740 46001478 2809791 2389583 3104071 839627 5913862 3229210 -5913862 -3229210 19649 197 29340 19649 29537 -5894213 -3199673 -5894213 -3199673 -0.72 -0.46 8157445 6920622 8100570 810 73220361 -28726207 44494964 63353 6 4607 4613 3434944 3434944 -5894213 -5894213 8163923 816 76659912 -34620420 42040308 6891608 689 21779340 -14239075 7540954 3868 1 3016 3017 51644 5 -5 23977 23977 -3199673 -3199673 6947120 695 21806328 -17438748 4368275 -5894213 -3199673 3434944 23977 312438 317473 240923 482709 -491005 535592 -3021789 -2474868 4613 3017 4613 3017 -3017176 -2471851 45686014 8074658 42668838 5602807 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1) Nature of Business and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio, <span style="white-space:pre-wrap;">Inc. (the “Company” or “Annovis”) is a clinical-stage drug platform company addressing Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and other chronic neurodegenerative diseases, including AD in Down syndrome (“AD-DS”). The Company’s lead compound, buntanetap, is a small, once a day, orally administered, brain penetrant compound. In several clinical and pre-clinical studies, buntanetap inhibited the synthesis of neurotoxic proteins—APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <span style="-sec-ix-hidden:Hidden_S9fxZHOlXkCaH5giVuH5DQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities. On May 26, 2021, the Company closed an underwritten public offering of 1,000,000 shares of its common stock at an offering price of $50.00 per share, for gross proceeds of $50.0<span style="white-space:pre-wrap;"> million. The net proceeds of the offering were approximately </span>$46.6<span style="white-space:pre-wrap;"> million, after deducting underwriting discounts and issuance costs. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date these financial statements are issued, management believes that the current cash and cash equivalents are sufficient to fund operations and capital requirements for at least the next 12 months including one planned six-month clinical trial in early PD patients and one potential short-term trial in early AD patients. To fund additional expected Phase 3 trials, however, the Company will need to raise additional capital. There is no assurance that such financing will be available when needed or on acceptable terms.</p> 1000000 50.00 50000000.0 46600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2) Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation of Interim Unaudited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2022, and its results of operations and its cash flows for the three months ended March 31, 2022 and 2021. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include stock-based compensation expense, progress toward completion of research and development projects, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)  Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h) Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i) Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2022 or December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. The adoption of this standard did not have a significant impact on the Company’s financial statements. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation of Interim Unaudited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at March 31, 2022, and its results of operations and its cash flows for the three months ended March 31, 2022 and 2021. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include stock-based compensation expense, progress toward completion of research and development projects, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Basic and Diluted Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)  Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(h) Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(i) Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(j) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at March 31, 2022 or December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(k) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new disclosure requirements include information about the nature of the transactions and the related accounting policy used to account for the transactions; the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and significant terms and conditions of the transactions, including commitments and contingencies. The guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and may be adopted prospectively or retrospectively. The adoption of this standard did not have a significant impact on the Company’s financial statements. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3) Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,668,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,686,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 42668838 42668838 45686014 45686014 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4) Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November <span style="white-space:pre-wrap;">2019. The Company recognized grant income of $0 and $29,340 for the three months ended March 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $0 and $29,340 during the three months ended March 31, 2022 and 2021, respectively. The Company recorded a grant receivable of $0 as of March 31, 2022 and December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of March 31, 2022, there were no remaining funds available under the grant.</span></p> 1900000 0 29340 0 29340 0 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5) Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 627,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 627,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 315,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 258361 232752 313119 29111 46557 43736 9865 9865 627902 315464 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6) Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 158,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional and clinical fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 158,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 818,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 168515 712768 158920 105672 327435 818440 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7) Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $17,276 and $10,615 for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics from a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Under the license agreement, the Company paid a minimum annual fee of $46,000 and was required to make milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Licensor also granted the Company a buy-out option which was exercisable at any time during the term of the agreement at increasing amounts based on the achievement of certain milestones. The Company had the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. Expenses related to the license agreement were recognized in general and administrative expense in the statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In July 2021, the Company gave notice to the Licensor of its termination of the license agreement and the license agreement was terminated effective October 14, 2021. The Company has paid to the Licensor the prorated annual fees through the termination date. </span>No milestones had been achieved as of the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason The maximum aggregate severance payments under the agreements were approximately $986,000 at March 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2022, the Company did not have any pending legal actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e) Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent to which the COVID-19 pandemic could have a material impact on the Company’s current or future clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. Management continues to evaluate the potential impact. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 17276 10615 46000 P90D 0 986000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8) Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”), to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a <span style="-sec-ix-hidden:Hidden_Vx33PXd0v0yAbWcEnRfd6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">par value</span></span><span style="white-space:pre-wrap;"> of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">1.           Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">2.           Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">3.           Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of March 31, 2022 or December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with the closing of the Company’s IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">public offering price. The warrants have a </span><span style="white-space:pre-wrap;">five-year</span><span style="white-space:pre-wrap;"> term and were exercisable as of January 29, 2021. During the year ended December 31, 2021, 97,600</span><span style="white-space:pre-wrap;"> of the warrants were tendered to the Company by the holders pursuant to cashless exercises. As of March 31, 2022 and December 31, 2021, 2,400</span><span style="white-space:pre-wrap;"> of the warrants were outstanding. The Company accounts for the warrants as a component of stockholders’ equity.</span></p> 2 37000000 0.0001 35000000 2000000 1 0 0 100000 7.50 1.25 P5Y 97600 2400 2400 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9) Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective on January 31, 2020, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of March 31, 2022, 442,275 shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,245,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,977</p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,977</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three months ended March 31, 2022, the Company granted options to purchase 188,294 shares of common stock at an exercise price of $19.78 per share to employees, members of its board of directors and consultants. Under the grant agreements, the options generally vest in substantially equal quarterly installments over two years and have a <span style="-sec-ix-hidden:Hidden_wV-IgFQazUSMYioMFclcIQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span></span>-year term. The options granted during the three months ended March 31, 2022 were valued using the Black Scholes option pricing model using the following assumptions: (i) expected term of <span style="-sec-ix-hidden:Hidden_DlS8R5rh_kuDlGqy4odXyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</span></span> years; (ii) risk free interest rate of 1.42%; (iii) expected volatility of 114.0%; and (iv) dividend yield of 0.0<span style="white-space:pre-wrap;">%. The weighted-average grant date fair value of options issued by the Company during the three months ended March 31, 2022 was $16.36 per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock options exercised during the three months ended March 31, 2022 and 2021, were 70,101 and 3,868<span style="white-space:pre-wrap;">, respectively. As of March 31, 2022, there were 1,607,941 options outstanding, of which 1,211,193</span><span style="white-space:pre-wrap;"> were vested and exercisable. As of December 31, 2021, there were 1,489,748 options outstanding, of which 1,105,568 were vested and exercisable.</span></p> 0 1000000 2000000 442275 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,245,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,977</p></td></tr><tr><td style="vertical-align:bottom;width:73.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,434,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,977</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 2245043 23977 1189901 3434944 23977 188294 19.78 P2Y 0.0142 1.140 0.000 16.36 70101 3868 1607941 1211193 1489748 1105568 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199,673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,157,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,920,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_n1Qm921rZ0W4WFTw1tjLKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nZ0cMSImwkaoTDzGRixV4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company reported a net loss for the three months ended March 31, 2022 and 2021, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,607,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,107,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,894,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199,673)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,157,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,920,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_n1Qm921rZ0W4WFTw1tjLKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nZ0cMSImwkaoTDzGRixV4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> -5894213 -3199673 8157445 6920622 -0.72 -0.46 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,607,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,107,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 1607941 1107598 2400 5000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(11) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s income tax benefit (expense) was $0 for the three months ended March 31, 2022 and 2021. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three months ended March 31, 2022 and 2021 was offset by changes in the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March 31, 2022, and December 31, 2021, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.</p> 0 0 EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 57 158 1 false 17 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations Sheet http://annovisbio.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Statements of Changes in Stockholders' Equity Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Nature of Business and Liquidity Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 10401 - Disclosure - Grant Income Sheet http://annovisbio.com/role/DisclosureGrantIncome Grant Income Notes 10 false false R11.htm 10501 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 10601 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 10701 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 10801 - Disclosure - Stockholders' Equity Sheet http://annovisbio.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 10901 - Disclosure - Stock-Based Compensation Sheet http://annovisbio.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 11001 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 16 false false R17.htm 11101 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 21 false false R22.htm 30903 - Disclosure - Stock-Based Compensation (Tables) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://annovisbio.com/role/DisclosureStockBasedCompensation 22 false false R23.htm 31003 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 23 false false R24.htm 40101 - Disclosure - Nature of Business and Liquidity (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails Nature of Business and Liquidity (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity 24 false false R25.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://annovisbio.com/role/DisclosureFairValueMeasurementsTables 25 false false R26.htm 40401 - Disclosure - Grant Income (Details) Sheet http://annovisbio.com/role/DisclosureGrantIncomeDetails Grant Income (Details) Details http://annovisbio.com/role/DisclosureGrantIncome 26 false false R27.htm 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 27 false false R28.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 28 false false R29.htm 40701 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 29 false false R30.htm 40702 - Disclosure - Commitments and Contingencies - License Agreement (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails Commitments and Contingencies - License Agreement (Details) Details 30 false false R31.htm 40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails Commitments and Contingencies - Employment Agreements (Details) Details 31 false false R32.htm 40801 - Disclosure - Stockholders' Equity - Overview (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails Stockholders' Equity - Overview (Details) Details 32 false false R33.htm 40802 - Disclosure - Stockholders' Equity - Warrants (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails Stockholders' Equity - Warrants (Details) Details 33 false false R34.htm 40901 - Disclosure - Stock-Based Compensation (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://annovisbio.com/role/DisclosureStockBasedCompensationTables 34 false false R35.htm 41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 35 false false R36.htm 41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 36 false false R37.htm 41101 - Disclosure - Income Taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://annovisbio.com/role/DisclosureIncomeTaxes 37 false false All Reports Book All Reports anvs-20220331x10q.htm anvs-20220331.xsd anvs-20220331_cal.xml anvs-20220331_def.xml anvs-20220331_lab.xml anvs-20220331_pre.xml anvs-20220331xex31d1.htm anvs-20220331xex31d2.htm anvs-20220331xex32d1.htm anvs-20220331xex32d2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anvs-20220331x10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 57, "dts": { "calculationLink": { "local": [ "anvs-20220331_cal.xml" ] }, "definitionLink": { "local": [ "anvs-20220331_def.xml" ] }, "inline": { "local": [ "anvs-20220331x10q.htm" ] }, "labelLink": { "local": [ "anvs-20220331_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20220331_pre.xml" ] }, "schema": { "local": [ "anvs-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 249, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 26, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 33 }, "keyCustom": 23, "keyStandard": 135, "memberCustom": 5, "memberStandard": 11, "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Grant Income", "role": "http://annovisbio.com/role/DisclosureGrantIncome", "shortName": "Grant Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses", "role": "http://annovisbio.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Commitments and Contingencies", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Stockholders' Equity", "role": "http://annovisbio.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-Based Compensation", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Loss Per Share", "role": "http://annovisbio.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Income Taxes", "role": "http://annovisbio.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Balance Sheets", "role": "http://annovisbio.com/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses (Tables)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Loss Per Share (Tables)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_vB_BbV69EEue0lRWECa8iw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business and Liquidity (Details)", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "shortName": "Nature of Business and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_5_26_2021_To_5_26_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryPublicOfferingMember_vB_BbV69EEue0lRWECa8iw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value Measurements (Details)", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xGZVvqDw2EqONTipGvjaUg", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_7EUdI0i3akaxlHXeEeg2uA", "decimals": "0", "first": true, "lang": null, "name": "anvs:IncomeFromGrants", "reportCount": 1, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Grant Income (Details)", "role": "http://annovisbio.com/role/DisclosureGrantIncomeDetails", "shortName": "Grant Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "anvs:OtherNonoperatingIncomeGrantIncomeTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "lang": null, "name": "anvs:UnreimbursedEligibleCostsIncurredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses (Details)", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Commitments and Contingencies - Leases (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "shortName": "Commitments and Contingencies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_nXytuXxpxUiATWR3H6Y58w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Balance Sheets (Parenthetical)", "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_Sf3TPsQiJkiSwCKWsgsBSQ", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2020_To_11_30_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_eeqHK1RMIEuxDCWKGaOo-A", "decimals": "0", "first": true, "lang": null, "name": "anvs:LicenseAgreementMinimumAnnualCommitment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Commitments and Contingencies - License Agreement (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "shortName": "Commitments and Contingencies - License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2020_To_11_30_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_eeqHK1RMIEuxDCWKGaOo-A", "decimals": "0", "first": true, "lang": null, "name": "anvs:LicenseAgreementMinimumAnnualCommitment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_FROGQ371wES-A1IRHV4KFg", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "shortName": "Commitments and Contingencies - Employment Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_FROGQ371wES-A1IRHV4KFg", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_1_31_2020_kg6uwQ79MkeqdST1tMwmjg", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_FD6YEetrkUaXjp_glvvHpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Stockholders' Equity - Overview (Details)", "role": "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "shortName": "Stockholders' Equity - Overview (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_1_31_2020_kg6uwQ79MkeqdST1tMwmjg", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_FD6YEetrkUaXjp_glvvHpA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_sOwHWp92ZU2W7tUceP5sDg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Stockholders' Equity - Warrants (Details)", "role": "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails", "shortName": "Stockholders' Equity - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_UnderwritersWarrantsMember_sOwHWp92ZU2W7tUceP5sDg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-Based Compensation (Details)", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_3_31_2022__7rDf44wuk2ovZ0FwOlkfw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mc8aHDc7lkao-udPsMwTgQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)", "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_mc8aHDc7lkao-udPsMwTgQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V0jtn_kLXkOuiCU0RkfNqQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Income Taxes (Details)", "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Statements of Operations", "role": "http://annovisbio.com/role/StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X71bYK5IbUiIy95fUiT5Cg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Statements of Changes in Stockholders' Equity", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity", "shortName": "Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X71bYK5IbUiIy95fUiT5Cg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Statements of Cash Flows", "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Og7vbckFgUGHWzFQKreDNA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business and Liquidity", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity", "shortName": "Nature of Business and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value Measurements", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_YXY4659Az06bn51boWWk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 17, "tag": { "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock And Preferred Stock, Shares Authorized", "terseLabel": "Number of common and preferred shares authorized" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "sharesItemType" }, "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.", "label": "Conversion of Warrants, Number of Warrants Converted", "terseLabel": "Number of warrants converted in a non-cash transaction" } } }, "localname": "ConversionOfWarrantsNumberOfWarrantsConverted", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "anvs_CumulativeNumberOfMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cumulative number of milestones achieved.", "label": "Cumulative Number of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "localname": "CumulativeNumberOfMilestonesAchieved", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.", "label": "2019 Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_GrantAwardRemainingAmountAvailable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remining balance of funds available under a grant award.", "label": "Grant Award, Remaining Amount Available", "terseLabel": "Remining funds available" } } }, "localname": "GrantAwardRemainingAmountAvailable", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "monetaryItemType" }, "anvs_GrantIncomePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for grant income.", "label": "Grant Income [Policy Text Block]", "terseLabel": "Grant Income" } } }, "localname": "GrantIncomePolicyTextBlock", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_GrantsReceivableNoticeOfAwardAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of grant awarded.", "label": "Grants Receivable, Notice of Award Amount", "terseLabel": "Notice of Award, grant amount" } } }, "localname": "GrantsReceivableNoticeOfAwardAmount", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "monetaryItemType" }, "anvs_IncomeFromGrants": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Outside the scope of Topic 606.", "label": "Income from Grants", "terseLabel": "Grant income" } } }, "localname": "IncomeFromGrants", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.", "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]", "terseLabel": "Issuance Costs Associated with Equity Issuances" } } }, "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_LicenseAgreementMinimumAnnualCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of annual commitment under the terms of a license agreement.", "label": "License Agreement, Minimum Annual Commitment", "verboseLabel": "Minimum annual fee" } } }, "localname": "LicenseAgreementMinimumAnnualCommitment", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "anvs_LicenseAgreementPeriodOfAdvanceNoticeOfTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of advance notice required to terminate the license agreement.", "label": "License Agreement, Period of Advance Notice of Termination", "terseLabel": "Period for advance notice of termination" } } }, "localname": "LicenseAgreementPeriodOfAdvanceNoticeOfTermination", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "durationItemType" }, "anvs_MaximumAggregateSeverancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.", "label": "Maximum Aggregate Severance Payments", "terseLabel": "Maximum aggregate severance payments" } } }, "localname": "MaximumAggregateSeverancePayments", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_NationalInstituteOnAgingOfNationalInstitutesOfHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the National Institute on Aging of the National Institutes of Health.", "label": "NIH" } } }, "localname": "NationalInstituteOnAgingOfNationalInstitutesOfHealthMember", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "domainItemType" }, "anvs_NatureOfBusinessAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of Business and Liquidity [Abstract]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "NatureOfBusinessAndLiquidityAbstract", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "anvs_NonOperatingIncomeGrantIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Grant Income" } } }, "localname": "NonOperatingIncomeGrantIncomeAbstract", "nsuri": "http://annovisbio.com/20220331", "xbrltype": "stringItemType" }, "anvs_NumberOfClassesOfStockDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of classes of stock designated.", "label": "Number of classes of stock designated", "terseLabel": "Number of classes of stock designated" } } }, "localname": "NumberOfClassesOfStockDesignated", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "integerItemType" }, "anvs_NumberOfVotesForEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote for each share of common stock.", "label": "Number of Votes for Each Share of Common Stock", "terseLabel": "Number of vote for each share of common stock" } } }, "localname": "NumberOfVotesForEachShareOfCommonStock", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "integerItemType" }, "anvs_OtherNonoperatingIncomeGrantIncomeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the grant income classified as other non-operating income.", "label": "Other Nonoperating Income, Grant Income [Text Block]", "terseLabel": "Grant Income" } } }, "localname": "OtherNonoperatingIncomeGrantIncomeTextBlock", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncome" ], "xbrltype": "textBlockItemType" }, "anvs_PercentageOfExercisePriceToShareOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price to the share offering price.", "label": "Percentage of Exercise Price to the Share Offering Price", "terseLabel": "Percentage of exercise price to the share offering price" } } }, "localname": "PercentageOfExercisePriceToShareOfferingPrice", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "percentItemType" }, "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.", "label": "Prepaid Expense, Security Deposits, and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research and Development Expense, Current", "terseLabel": "Prepaid clinical trial expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenseCurrent", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_PreviousPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to previous plans.", "label": "Previous Plans" } } }, "localname": "PreviousPlansMember", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_ProceedsFromGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from grants.", "label": "Proceeds from Grants" } } }, "localname": "ProceedsFromGrants", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "monetaryItemType" }, "anvs_SecondaryPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secondary sale of stock.", "label": "Secondary Public Offering" } } }, "localname": "SecondaryPublicOfferingMember", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "domainItemType" }, "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Cashless exercise of warrants, shares", "verboseLabel": "Shares issued upon exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "anvs_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Cashless exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "anvs_UnderwritersWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Underwriters warrants.", "label": "Underwriters warrants" } } }, "localname": "UnderwritersWarrantsMember", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "anvs_UnreimbursedEligibleCostsIncurredDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of unreimbursed eligible costs incurred during the period.", "label": "Unreimbursed Eligible Costs Incurred During the Period", "terseLabel": "Unreimbursed, eligible costs incurred under the grant" } } }, "localname": "UnreimbursedEligibleCostsIncurredDuringPeriod", "nsuri": "http://annovisbio.com/20220331", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "label": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r114", "r266" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r22", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r25" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional and clinical fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r207", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r61", "r62", "r63", "r204", "r205", "r206", "r245" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r57", "r100", "r103", "r109", "r116", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r236", "r240", "r257", "r267", "r269", "r276", "r283" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r32", "r57", "r116", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r236", "r240", "r257", "r267", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r186", "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "verboseLabel": "Basis of Presentation of Interim Unaudited Financial Statements" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r19", "r51" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r47", "r51", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r47", "r258" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r170", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r170", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Grant Income" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r127", "r278", "r286" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r124", "r125", "r126", "r128", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r61", "r62", "r245" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Number of common shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangements [Abstract]", "terseLabel": "Employment Agreements" } } }, "localname": "DeferredCompensationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r66", "r67", "r68", "r69", "r70", "r74", "r76", "r78", "r79", "r80", "r84", "r85", "r246", "r247", "r281", "r288" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic loss per common share", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r41", "r66", "r67", "r68", "r69", "r70", "r76", "r78", "r79", "r80", "r84", "r85", "r246", "r247", "r281", "r288" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per common share", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r81", "r82", "r83", "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r36", "r37", "r38", "r61", "r62", "r63", "r65", "r71", "r73", "r87", "r117", "r162", "r169", "r204", "r205", "r206", "r225", "r226", "r245", "r259", "r260", "r261", "r262", "r263", "r264", "r291", "r292", "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r140", "r141", "r142", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r249", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r248", "r249", "r251", "r252", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r140", "r176", "r177", "r182", "r183", "r249", "r270" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r140", "r141", "r142", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable, Current", "terseLabel": "Grant receivable" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r39", "r100", "r102", "r105", "r108", "r110", "r275", "r279", "r282", "r289" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r58", "r217", "r220", "r223", "r227", "r229", "r231", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r59", "r72", "r73", "r99", "r216", "r228", "r230", "r290" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r35", "r214", "r215", "r220", "r221", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r49" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r49" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Leases" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r57", "r104", "r116", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r237", "r240", "r241", "r257", "r267", "r268" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r57", "r116", "r257", "r269", "r277", "r285" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' ' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r57", "r116", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r237", "r240", "r241", "r257", "r267", "r268", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r47" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r48", "r50" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r34", "r38", "r40", "r50", "r57", "r64", "r66", "r67", "r68", "r69", "r72", "r73", "r77", "r100", "r102", "r105", "r108", "r110", "r116", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r247", "r257", "r280", "r287" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r100", "r102", "r105", "r108", "r110" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rental expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r119" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r186", "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r146" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r146" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r7", "r118", "r119" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Gross proceeds from issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r45", "r203" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r33", "r34", "r38", "r46", "r57", "r64", "r72", "r73", "r100", "r102", "r105", "r108", "r110", "r116", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r235", "r238", "r239", "r242", "r243", "r247", "r257", "r282" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r211", "r273", "r297" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r20", "r120", "r121", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r169", "r207", "r269", "r284", "r294", "r295" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r61", "r62", "r63", "r65", "r71", "r73", "r117", "r204", "r205", "r206", "r225", "r226", "r245", "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r97", "r98", "r101", "r106", "r107", "r111", "r112", "r113", "r172", "r173", "r274" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from issuance of common shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r185", "r201", "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r186", "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r28", "r55", "r88", "r89", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r151", "r155", "r160", "r163", "r164", "r165", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r31" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r192", "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r184", "r190" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of award (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r196", "r208" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r60" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r36", "r37", "r38", "r61", "r62", "r63", "r65", "r71", "r73", "r87", "r117", "r162", "r169", "r204", "r205", "r206", "r225", "r226", "r245", "r259", "r260", "r261", "r262", "r263", "r264", "r291", "r292", "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Changes in Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r61", "r62", "r63", "r87", "r274" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r162", "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r162", "r169", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r29", "r162", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r57", "r115", "r116", "r257", "r269" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r56", "r147", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r161", "r169", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureGrantIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Liability for uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r90", "r91", "r92", "r93", "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r75", "r80" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding, diluted", "verboseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r74", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding, basic", "verboseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r298": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r299": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r301": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r302": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r303": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r304": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" } }, "version": "2.1" } ZIP 56 0001558370-22-006981-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-006981-xbrl.zip M4$L#!!0 ( %I=I%2+95DO- P +AO 1 86YV>7ZX'G..O)ML$31=NDNX&2&HCR>[V;4%+M$VL)+HD MY3CWU]^0$B5;'Y1D-Q<#IY?6%F>&,_,CAS,40W_\>>-[:$VXH"RX[ Q.^AU$ M H>Y-%A<=D+1Q<*AM//SI[__[>,_NMUOGQ_ND,N!1 XG6!(7/5.Y1$]L MM<(!NB><4\]#GSEU%P2A\Y.SDP^#P?G)<'#VTRGJ=F-)G[$ 3A8@+7)X,DA: MKF*I++A I[WWO6%_.$2CB]&'B]$03>\3NGM08X]"0X M)?@>8D]W#;[RB'+%#L%6,S@W$!>@0]+9\_/SR?/HA/$%=-0?]+[=WSUJ]0RQ M1X._=J@W,^X9^E%/-<_ =X:TVW6DO:C2D 5DH!$KE MGO@-75.%M;8@L'Y M^7E/MQI2P657OJR(R/LG:2KPD"MYAFU'(6CNJ6;%V5>%80E 1W:$**K�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end

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